---
title: Blood test tracks Parkinson progression
nct_id: NCT06941012
status: RECRUITING
sponsor: Casa di Cura IGEA
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06941012"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06941012"
last_fetched: "2026-05-10T14:06:03.545Z"
source: "Parkinson's Pathways (curated)"
---
# Blood test tracks Parkinson progression

**Goal (in five words):** Blood test tracks Parkinson progression

**Official Title:** Validation of α-synuclein Modifications in Parkinson's dIsoRder Evolution (VaMPiRE)

**Trial ID:** [NCT06941012](https://clinicaltrials.gov/study/NCT06941012)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Casa di Cura IGEA
- **Target Enrollment:** 1200 participants
- **Start Date:** 2025-05-12
- **Completion Date:** 2028-11-30
- **Conditions:** Parkinson Disease (PD)
- **Interventions:** Blood draw for the laboratory assessment
- **Intervention Types:** OTHER

## Summary For Families

VaMPiRE aims to find whether specific chemical modifications of the α-synuclein protein in blood track Parkinson's progression or can help tell people with PD apart from those without. The team will collect blood samples to measure modified forms of α-synuclein, the protein that misfolds and clumps in Parkinson's, looking for patterns linked to symptom severity or disease stage; this is observational only and does not change medications or interact with levodopa. Adults 18 to 85 are eligible, including people with PD diagnosed by MDS-UPDRS and Hoehn and Yahr stages I,IV while on meds, plus neurologically normal controls, with exclusions for severe cognitive decline, active infections, other confounding neurological conditions, or life‑threatening illnesses.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 85 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* • For PD subjects

  * PD diagnosis according to MDS-UPDRS criteria and Hoehn and Yahr scale between I-IV (MED ON) for PD subjects
  * Willing to participate. Participation is always voluntary.
  * Willing and able to provide written informed consent to participate in the study or having a legal representative responsible for signing; the participant (or the legal representative) must understand the purpose, methods, and all information regarding the study.
  * For non-PD subjects
  * Normal neurological examination findings.
  * Medical record (recent and remote medical history) available and reviewable by clinicians during the entire study period.
  * Willing and able to provide written informed consent to participate in the study

Exclusion Criteria:

* • For PD and non-PD subjects

  * Clinically significant and severe cognitive decline and/or intellectual disability which can lead to impairment not caused by Parkinson's disease or any other disease that could better explain the patient's symptoms; The exclusion criteria involve neurological and neurodevelopmental disorders including disorders of the brain, spinal cord, peripheral nerve, and muscle (e.g. cerebral palsy, epilepsy \[seizure disorders\], stroke, intellectual disability, moderate to severe developmental delay, muscular dystrophy, or spinal cord injury).
  * Fever (Temperature 38.0 °C (tympanic)).
  * Acute infection (such as Flu, COVID-19) which could debilitate the patient and affect the data.
  * Individuals with concurrent infections requiring systemic antimicrobial and/or antiviral therapy at the pre-dose examinations (e.g. HepC, HIV, TB).
  * Life-threatening co-existing disease with life expectancy, which could lead to premature dropout.
  * Any other neurological or systemic conditions that could confound results.
```

## Locations (4)

- Aristotle University of Thessaloniki, Thessaloniki, Greece _(40.6407, 22.9349)_
  - Savvas Petanidis — (CONTACT) — 0030 2310999205 — spetanid@auth.gr
- Casa di Cura Igea, Milan, Mi, Italy _(45.4643, 9.1895)_
  - Elda Judica, MD — (CONTACT) — 0039 02 48593242 — e.judica@casadicuraigea.it
- Instytut Psychiatrii I Neurologii, Warsaw, Poland _(52.2298, 21.0118)_
  - Tomasz Stępień — (CONTACT) — 0048 22458 25 00 — tstepien@ipin.edu.pl
- Asociacion Parkinson Madrid, Madrid, Spain _(40.4165, -3.7026)_
  - Mayca Marin Valero — (CONTACT) — 0034 914 340406 — investigacion@parkinsonmadrid.org

## Central Contacts

- Elda Judica, MD — (CONTACT) — +39 0248593242 — e.judica@casadicuraigea.it
- Annunziata Tramontano — (CONTACT) — 0039 0248593197 — a.tramontano@casadicuraigea.it

---

*Canonical: https://parkinsonspathways.com/trial/NCT06941012*  
*HTML version: https://parkinsonspathways.com/trial/NCT06941012*  
*Source data: https://clinicaltrials.gov/study/NCT06941012*